IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a leading global medical innovator, and Qualcomm Technologies, Inc., whose Snapdragon® branded platforms power extraordinary consumer experiences, today announced that Masimo is partnering with Qualcomm Technologies to develop a next-generation smartwatch reference platform for original equipment manufacturers (OEMs) building Wear OS by Google smartwatches.

加利福尼亚州欧文市（商业新闻短讯）--全球领先的医疗创新厂商Masimo（纳斯达克：MASI）和高通技术公司（Qualcomm Technologies，Inc.）今天宣布，Masimo正在与高通技术公司合作，为谷歌智能手表的原始设备制造商（OEM）构建Wear操作系统开发下一代智能手表参考平台。

The powerhouse combination of Masimo’s clinically proven, breakthrough biosensing technologies – based on its decades of expertise designing industry-leading hospital monitoring solutions – and best-in-class Snapdragon wearable platforms will help scale the wearable ecosystem. Forging the future of wearable devices, the reference platform will allow OEMs to more efficiently build and bring high-performing, premium smartwatches to market.

Masimo经过临床验证的突破性生物传感技术（基于其数十年来设计业界领先的医院监测解决方案的专业知识）与一流的Snapdragon可穿戴平台的强大结合将有助于扩展可穿戴生态系统。打造可穿戴设备的未来，该参考平台将使原始设备制造商能够更有效地构建高性能、高端智能手表，并将其推向市场。

The platform will also benefit from a robust suite of Masimo health and wellness tracking tools that consumers can trust to provide accurate, reliable data; it will use exclusively high-performance and ultra-low power system-on-a-chips (SoCs) alongside industry-leading wireless and cellular communications from Qualcomm Technologies to enable a superior connectivity experience..

该平台还将受益于一套强大的Masimo健康和健康跟踪工具，消费者可以信赖这些工具提供准确可靠的数据；它将专门使用高通技术公司提供的高性能和超低功耗片上系统（SoCs）以及业界领先的无线和蜂窝通信，以实现卓越的连接体验。。

Joe Kiani, Founder and CEO of Masimo, said, “We’re thrilled to be able to partner with Qualcomm Technologies, to whom we naturally turned to supply the chips in our own forthcoming Masimo Freedom™ wearable, to craft a truly remarkable reference platform. It’s a platform driven by the belief that when key smartwatch components are supplied by the leading experts in their field, the harmonious whole produces something even greater than the sum of those excellent parts.

Masimo创始人兼首席执行官乔·基亚尼（JoeKiani）表示：“我们很高兴能够与高通技术公司（Qualcomm Technologies）合作，我们很自然地转向高通技术公司（Qualcomm Technologies）为我们即将推出的Masimo Freedom™可穿戴设备提供芯片，以打造一个真正卓越的参考平台。该平台的理念是，当智能手表的关键组件由其领域的顶尖专家提供时，和谐的整体产生的东西甚至比这些优秀部件的总和还要大。

In short, Qualcomm Technologies and Masimo engineers are working together to optimize the ‘guts’ of the smartwatch. Masimo’s ability to craft precision monitoring technologies and advanced signal processing algorithms, combined with meticulously engineered, high-performing, low-power Snapdragon systems, is a compelling foundation.

简而言之，高通技术公司（Qualcomm Technologies）和Masimo的工程师正在共同努力，优化智能手表的“胆量”。Masimo能够精心设计精密监测技术和先进的信号处理算法，并结合精心设计的高性能低功耗Snapdragon系统，这是一个令人信服的基础。

We expect this new wearable platform to supercharge smartwatch OEMs’ abilities to create competitive, desirable smartwatches for consumers everywhere. I look forward to partnering with a company as well known for its commitment to innovation as Masimo.”.

我们预计，这个新的可穿戴平台将增强智能手表原始设备制造商的能力，为世界各地的消费者创造有竞争力、令人向往的智能手表。我期待与Masimo这样一家致力于创新的公司合作。”。

Dino Bekis, Vice President and General Manager, Wearables and Mixed Signal Solutions at Qualcomm Technologies, Inc., said, “Beginning with Snapdragon W5+ Gen 1, this collaboration will significantly broaden the range of smartwatch choices for consumers and further enhance the already exceptional Wear OS experience.

高通技术公司（Qualcomm Technologies，Inc.）可穿戴设备和混合信号解决方案副总裁兼总经理迪诺·贝基斯（Dino Bekis）表示：“从Snapdragon W5+Gen 1开始，此次合作将大大拓宽消费者对智能手表的选择范围，并进一步增强已经异常的穿戴操作系统体验。

With these reference designs, OEMs will benefit from robust, production-ready designs, incorporating Masimo’s state-of-the-art biosensing technology and Qualcomm Technologies’ leading Snapdragon wearable platforms. It will ultimately enable them to seamlessly bring their smartwatches to market rapidly and at scale.”.

有了这些参考设计，原始设备制造商将受益于强大的、可生产的设计，其中包括Masimo最先进的生物传感技术和高通技术公司领先的Snapdragon可穿戴平台。这将最终使他们能够无缝地将智能手表快速、大规模地推向市场。”。

OEMs who adopt the new reference platform will continue to design and produce their new smartwatches’ physical exteriors and have creative control over the appearance of the user interface. The devices’ interiors, including Snapdragon wearable platforms and Masimo biosensors, will be designed, provided, and tested by Masimo to ensure premium performance and an unmatched user experience.

采用新参考平台的OEM将继续设计和生产新智能手表的物理外观，并对用户界面的外观进行创造性控制。这些设备的内部，包括Snapdragon可穿戴平台和Masimo生物传感器，将由Masimo设计、提供和测试，以确保卓越的性能和无与伦比的用户体验。

Health and wellness capabilities will feature the same biosensing innovations and analytics that power Masimo W1® and forthcoming Masimo Freedom – technology based on Masimo’s clinically proven, industry-leading Signal Extraction Technology® (SET®). The Masimo reference platform will make all of these components, features, and benefits available for Wear OS smartwatch manufacturers in an easy-to-implement, standardized package..

健康和健康功能将采用与Masimo W1®和即将推出的Masimo Freedom相同的生物传感创新和分析技术，该技术基于Masimo经过临床验证的行业领先信号提取技术®（SET®）。Masimo参考平台将以易于实施的标准化软件包为Wear OS smartwatch制造商提供所有这些组件、功能和优点。。

Snapdragon is a trademark or registered trademark of Qualcomm Incorporated. Snapdragon is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.

。Snapdragon是高通技术公司和/或其子公司的产品。

Wear OS by Google is a trademark of Google LLC.

Google的Wear OS是Google LLC的商标。

@Masimo | #Masimo

@马西莫。#马西莫

About Masimo

关于Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio.

Masimo（纳斯达克股票代码：MASI）是一家全球医疗技术公司，开发和生产各种行业领先的监测技术，包括创新的测量、传感器、患者监护仪以及自动化和连接解决方案。此外，Masimo Consumer Audio拥有八个传奇音频品牌，包括Bowers&Wilkins、Denon、Marantz和Polk Audio。

Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns,3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-5 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at all 10 top U.S.

我们的使命是改善生活，改善患者预后，降低护理成本。1995年推出的Masimo SET®运动测量和低灌注™脉搏血氧仪已在100多项独立和客观的研究中显示，其性能优于其他脉搏血氧仪技术。1 Masimo SET®也被证明可以帮助临床医生减少新生儿严重的早产儿视网膜病变，2改善新生儿的CCHD筛查，3当在手术后病房使用Masimo Patient SafetyNet™进行连续监测时，可以减少快速反应团队的激活，ICU的转移和成本。4-5 Masimo SET®估计可用于全球领先医院和其他医疗机构的2亿多患者，6并且是前10位的主要脉搏血氧仪美国。

hospitals as ranked in the 2024 Newsweek World’s Best Hospitals listing.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™).

在2024年《新闻周刊》全球最佳医院名单中排名第一的医院。7 2005年，Masimo引入了rainbow®脉搏CO血氧测定技术，可以无创连续监测以前只能有创测量的血液成分，包括总血红蛋白（SpHb®），氧含量（SpOC™），羧基血红蛋白（SpCO®），高铁血红蛋白（SpMet®），Pleth变异指数（PVi®），RPVi™（rainbow®PVi）和氧储备指数（ORi™）。

In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate.

2013年，Masimo推出了Root®患者监测和连接平台，该平台从头开始构建，尽可能灵活和可扩展，以方便使用。

References

参考文献

Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.

已发表的脉搏血氧仪临床研究和Masimo SET®的益处可以在我们的网站上找到。比较研究包括独立和客观的研究，这些研究由科学会议上发表的摘要和同行评审的期刊文章组成。

Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.

Castillo A等人。通过改变临床实践和SpO2技术预防早产儿视网膜病变。儿科学报。2011年2月；100（2）：188-92。

de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.

de Wahl-Granelli A等人。脉搏血氧仪筛查对导管依赖性先天性心脏病检测的影响：一项针对39821名新生儿的瑞典前瞻性筛查研究。英国医学杂志。2009年；1月8日；338

McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.

McGrath S等人。普通护理病房的监测管理：策略，设计和实施。质量和患者安全联合委员会杂志。2016年7月；42（7）：293-302。

McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar.

McGrath S等人。与镇静和镇痛药物相关的住院呼吸骤停：持续监测对患者死亡率和严重发病率的影响。J患者Saf。2020年3月14日。

Estimate: Masimo data on file.

估计：Masimo数据存档。

https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states

https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states

Forward-Looking Statements

前瞻性声明

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the future development, efficiency, potential performance and adoption of the new Masimo reference platform (the “Platform”) and Masimo’s collaboration with Qualcomm.

本新闻稿包括1933年《证券法》第27A节和1934年《证券交易法》第21E节中定义的与1995年《私人证券诉讼改革法》相关的前瞻性声明。这些前瞻性声明包括关于新Masimo参考平台（“平台”）的未来发展、效率、潜在性能和采用以及Masimo与高通公司合作的声明。

These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our belief that Masimo's unique noninvasive measurement technologies, including the Platform, contribute to accurate, reliable data; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to the assumption that the Platform will be available for integration into future OEM smartwatches; risks related to our belief that the Platform and OEMs will benefit from the collaboration with Qualcomm; risks related to COVID-19; as well as other factors discussed in the 'Risk Factors' section of our most recent reports filed with the Securities and Exchange Commission ('SEC'), which may be obtained for free at the SEC's website at www.sec.gov.

这些前瞻性陈述基于对影响我们的未来事件的当前预期，并受到风险和不确定性的影响，所有这些都难以预测，其中许多超出了我们的控制范围，并且由于各种风险因素，可能导致我们的实际结果与我们前瞻性陈述中表达的结果产生重大不利影响，包括但不限于：与我们认为Masimo独特的非侵入性测量技术（包括平台）有助于准确可靠的数据有关的风险；与我们相信Masimo非侵入性医疗突破提供成本效益高的解决方案和独特优势有关的风险；与平台可用于集成到未来OEM智能手表的假设相关的风险；与我们相信平台和OEM将从与高通公司的合作中受益有关的风险；与新型冠状病毒相关的风险；以及我们向美国证券交易委员会（“SEC”）提交的最新报告中“风险因素”部分讨论的其他因素，这些因素可以在SEC的网站www.SEC.gov上免费获得。

Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove c.

。